Лечащий Врач (Nov 2023)

Cardiorenal relationships in patients with chronic heart failure with preserved ejection fraction

  • Yu. N. Panina,
  • V. I. Vishnevsky

DOI
https://doi.org/10.51793/os.2023.26.10.012
Journal volume & issue
Vol. 0, no. 10
pp. 78 – 81

Abstract

Read online

The combination of heart and kidney diseases caused by chronic heart failure and aggravated by kidney damage, called cardiorenal syndrome, is increasingly recognized as a critical pathological unit, leading to a worsening of the prognosis in patients with chronic heart failure with a preserved left ventricular ejection fraction of the heart. The pathogenesis, prognostic predictors and treatment methods have not yet been sufficiently studied, which makes studies of cattle in patients with chronic heart failure with a preserved left ventricular ejection fraction of the heart extremely relevant. The ultimate goal of research is to reduce the burden of disease through prediction, prevention and effective treatment. This work is aimed at reviewing current research in the field of pathogenesis and methods of diagnosis and treatment of cardiorenal relationships in patients with chronic heart failure with preserved left ventricular ejection fraction. The problem with cardiorenal syndrome in patients with chronic heart failure makes it necessary to develop and implement new approaches to nephroprotection. The initial level of creatinine and urea in plasma, especially its increase during hospitalization, is a marker of deterioration of kidney function. New targeted therapies, such as angiotensin/neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors, offer new opportunities to realize potential benefits in reducing cardiac and renal adverse outcomes. Until recently, there were no specific therapeutic agents for patients with cardiorenal syndrome and chronic heart failure. New targeted therapies open up new opportunities to realize potential benefits in reducing cardiac and renal adverse outcomes in patients with chronic heart failure. Randomized clinical trials aimed at patients with chronic heart failure are continuing in order to identify optimal new treatments that may change their prognosis.

Keywords